D
Deleted member 48881
Guest
World's media ask how it went so wrong for 'Plague Island' Britain
Boris Johnson comes under fire as countries suspend travel from UK over new Covid variant
Well I read it and this seems like a relevant bit - as far as I’m aware these extra trials are taking place and, whilst noting limitations, the authors do say “hard not to be excited by the findings” which seems a long way from your “Oxford vaccine not what we need” statement"But I have no medical training - I have no idea how big/small some of these factors would be so given a choice between you, me or the scientists I’m betting in the latter to know what they are talking about!"
But it's the peer review by scientists that flagged up the imbalance in demographic, not me.
I would urge you and others to read this article:
Bloomberg - Are you a robot?
www.bloomberg.com
Further trials to substantiate the findings and an investigation of efficacy in older adults are needed, Maria Deloria Knoll and Chizoba Wonodi of the Johns Hopkins Bloomberg School of Public Health wrote in an article accompanying the data.
The authors noted “limitations” with the results, including less than 4% of participants who were older than 70 years of age, as well as the finding that no participants older than 55 received the mixed-dose regimen. Still, they said that the expected lower price of the vaccine holds promise for lower- and middle-income nations.
“Despite the outstanding questions and challenges in delivering these vaccines, it is hard not to be excited about these findings and the existence of three safe and efficacious Covid-19 vaccines,” they wrote.
![]()
World's media ask how it went so wrong for 'Plague Island' Britain
Boris Johnson comes under fire as countries suspend travel from UK over new Covid variantwww.theguardian.com
Yeah but we’re “Great” Britain. We do have government ministers telling the EU that we are a better country than them.Bit rich when all of Europe is in lockdown
Once we've vaccinated the elderly and vulnerable we should have eliminated the vast majority of hospitalisations and deaths. I think it's somewhere around 9 million to eliminate 70% of those admissions.This is getting me down, I'm constantly worrying about the vulnerable family members. Will this ever end
EU isn’t a country, so our govt ministers would be almost 100% correct (which is rare)... if Great Britain were a country... which it isn’t.Yeah but we’re “Great” Britain. We do have government ministers telling the EU that we are a better country than them.
Yeah but we’re “Great” Britain. We do have government ministers telling the EU that we are a better country than them.
Tesco have now put the limits on a few items again.
Bog rolls, pasta, same as the last time everyone panicked.
Yes, and that related to the general prospect of getting a higher than 70% efficacy for the overwhelmingly younger groups they used for participation in the low-high dosage trials. It doesn't say they were "excited" about the vaccine where older age groups were concerned.Well I read it and this seems like a relevant bit - as far as I’m aware these extra trials are taking place and, whilst noting limitations, the authors do say “hard not to be excited by the findings” which seems a long way from your “Oxford vaccine not what we need” statement
So I dug out their full article hereYes, and that related to the general prospect of getting a higher than 70% efficacy for the overwhelmingly younger groups they used for participation in the low-high dosage trials. It doesn't say they were "excited" about the vaccine where older age groups were concerned.
So with that Dave I am going to await the Phase 3 results and not get drawn into this discussion any further.Neutralising antibody titres after a boost dose were similar across all age groups (median MNA80 at day 42 in the standard-dose groups: 18–55 years, 193 [IQR 113–238], n=39; 56–69 years, 144 [119–347], n=20; and ≥70 years, 161 [73–323], n=47; p=0·40). By 14 days after the boost dose, 208 (>99%) of 209 boosted participants had neutralising antibody responses. T-cell responses peaked at day 14 after a single standard dose of ChAdOx1 nCoV-19 (18–55 years: median 1187 spot-forming cells [SFCs] per million peripheral blood mononuclear cells [IQR 841–2428], n=24; 56–69 years: 797 SFCs [383–1817], n=29; and ≥70 years: 977 SFCs [458–1914], n=48).
Interpretation
ChAdOx1 nCoV-19 appears to be better tolerated in older adults than in younger adults and has similar immunogenicity across all age groups after a boost dose. Further assessment of the efficacy of this vaccine is warranted in all age groups and individuals with comorbidities.
And to you and yours!So I dug out their full article here
And to me they don’t seem to have concerns about the trial design or any indicatiion that results will be worse for older age groups, just that they would like some further testing to be confident.
I went and looked at some of the early data
and the follow ups that involved older groups
And there didn’t seem to be any flags about the elderly, in fact if anything the elderly seemed to have less side effects with no difference in antibody responses
So with that Dave I am going to await the Phase 3 results and not get drawn into this discussion any further.
Wishing you and the family a pleasant Christmas.
Join the Everton conversation today.
Fewer ads, full access, completely free.